To this end, the reduction of daily OFF time is a meaningful goal in the treatment of middle and advanced stage PD and has been chosen as the primary endpoint in the majority of clinical trials with MAO and COMT inhibitors. This evidence concerns the gene COMT and Parkinson disease.